BACKGROUND: Response to challenge with live, attenuated, oral polio vaccine (OPV) is a measure of immunity induced by prior immunization. METHODS: Using stool samples from a study from Oman in which an initial schedule of inactivated polio vaccine (IPV) was followed by an OPV type 1 challenge, we quantitated virus shed, sequenced capsid proteins of recovered virus, and developed assays for neutralization of poliovirus and mucosal immunoglobulin A (IgA) detection. RESULTS: Neutralizing activity correlated with detection of polio-specific IgA in stool suspensions collected 7 days after OPV type 1 challenge. Both neutralization and IgA in stool were associated with cessation of virus shedding by day 7. Rapid development of an IgA response with cessation of shedding suggests that IPV primed for the early response to challenge. Correlation of neutralization activity and IgA detection provides evidence that polio-specific IgA intestinal antibody is a determinant of mucosal shedding/transmission and that IgA functions through neutralization of virus. In contrast, neither presence nor quantity of serum or intestinal antibody induced by IPV prior to challenge correlated with cessation of shedding. CONCLUSIONS: These assays provide an opportunity to study other immunization schedules to gain a broader understanding of the appearance and duration of a protective mucosal response to polio vaccination.
BACKGROUND: Response to challenge with live, attenuated, oral polio vaccine (OPV) is a measure of immunity induced by prior immunization. METHODS: Using stool samples from a study from Oman in which an initial schedule of inactivated polio vaccine (IPV) was followed by an OPV type 1 challenge, we quantitated virus shed, sequenced capsid proteins of recovered virus, and developed assays for neutralization of poliovirus and mucosal immunoglobulin A (IgA) detection. RESULTS: Neutralizing activity correlated with detection of polio-specific IgA in stool suspensions collected 7 days after OPV type 1 challenge. Both neutralization and IgA in stool were associated with cessation of virus shedding by day 7. Rapid development of an IgA response with cessation of shedding suggests that IPV primed for the early response to challenge. Correlation of neutralization activity and IgA detection provides evidence that polio-specific IgA intestinal antibody is a determinant of mucosal shedding/transmission and that IgA functions through neutralization of virus. In contrast, neither presence nor quantity of serum or intestinal antibody induced by IPV prior to challenge correlated with cessation of shedding. CONCLUSIONS: These assays provide an opportunity to study other immunization schedules to gain a broader understanding of the appearance and duration of a protective mucosal response to polio vaccination.
Authors: Peter F Wright; Anne G Hoen; Natalia A Ilyushina; Eric P Brown; Margaret E Ackerman; Wendy Wieland-Alter; Ruth I Connor; Sinthujan Jegaskanda; Yael Rosenberg-Hasson; Brenda C Haynes; Catherine J Luke; Kanta Subbarao; John J Treanor Journal: Open Forum Infect Dis Date: 2016-05-23 Impact factor: 3.835
Authors: Peter F Wright; Ruth I Connor; Wendy F Wieland-Alter; Anne G Hoen; Austin W Boesch; Margaret E Ackerman; M Steven Oberste; Chris Gast; Elizabeth B Brickley; Edwin J Asturias; Ricardo Rüttimann; Ananda S Bandyopadhyay Journal: Lancet Infect Dis Date: 2016-09-13 Impact factor: 25.071
Authors: Elizabeth B Brickley; Carolyn B Strauch; Wendy F Wieland-Alter; Ruth I Connor; Shu Lin; Joshua A Weiner; Margaret E Ackerman; Minetaro Arita; M Steven Oberste; William C Weldon; Xavier Sáez-Llorens; Ananda S Bandyopadhyay; Peter F Wright Journal: J Infect Dis Date: 2018-01-17 Impact factor: 5.226
Authors: Eric P Brown; Karen G Dowell; Austin W Boesch; Erica Normandin; Alison E Mahan; Thach Chu; Dan H Barouch; Chris Bailey-Kellogg; Galit Alter; Margaret E Ackerman Journal: J Immunol Methods Date: 2017-02-03 Impact factor: 2.303
Authors: Jessica A White; Jeremy S Blum; Nancy A Hosken; Joshua O Marshak; Lauren Duncan; Changcheng Zhu; Elizabeth B Norton; John D Clements; David M Koelle; Dexiang Chen; William C Weldon; M Steven Oberste; Manjari Lal Journal: Hum Vaccin Immunother Date: 2014 Impact factor: 3.452
Authors: Ayan Dey; Natalie A Molodecky; Harish Verma; Prashant Sharma; Jae Seung Yang; Giulietta Saletti; Mohammad Ahmad; Sunil K Bahl; Thomas F Wierzba; Ranjan K Nandy; Jagadish M Deshpande; Roland W Sutter; Cecil Czerkinsky Journal: PLoS One Date: 2016-01-05 Impact factor: 3.240
Authors: Rami Yaari; Ehud Kaliner; Itamar Grotto; Guy Katriel; Jacob Moran-Gilad; Danit Sofer; Ella Mendelson; Elizabeth Miller; Amit Huppert; E Anis; E Kopel; Y Manor; O Mor; L Shulman; R Singer; M Weil Journal: BMC Med Date: 2016-06-23 Impact factor: 8.775
Authors: Ananda S Bandyopadhyay; Edwin J Asturias; Miguel O'Ryan; M Steven Oberste; William Weldon; Ralf Clemens; Ricardo Rüttimann; John F Modlin; Chris Gast Journal: Vaccine Date: 2017-11-14 Impact factor: 3.641
Authors: James A Church; Sandra Rukobo; Margaret Govha; Marya P Carmolli; Sean A Diehl; Bernard Chasekwa; Robert Ntozini; Kuda Mutasa; Jean H Humphrey; Beth D Kirkpatrick; Andrew J Prendergast Journal: Hum Vaccin Immunother Date: 2017-08-31 Impact factor: 3.452